Savara (SVRA) Tax Provisions (2017 - 2018)
Savara (SVRA) posted quarterly Tax Provisions of $2.5 million for Q4 2018, up 188.97% year-over-year from $865147.8 in Q4 2017, and up 2372.73% quarter-over-quarter from -$110000.0 in Q3 2018.
Powered by 
Analysis
Savara (SVRA) Tax Provisions (2017 - 2018) Analysis & Trends
Savara (SVRA) has reported Tax Provisions for 2 consecutive years, with $2.5 million the latest figure, recorded in Q4 2018.
- In Q4 2018, Tax Provisions rose 188.97% year-over-year to $2.5 million; the TTM figure through Dec 2018 stood at -$2.4 million (up 32.8% YoY), while the FY2019 annual figure was -$16.4 million, down 13338.71% from the prior year.
- Tax Provisions grew to $2.5 million in Q4 2018 per SVRA's latest filing, from -$110000.0 in the prior quarter.
- Across five years, Tax Provisions topped out at $2.5 million in Q4 2018 and bottomed at -$4.6 million in Q1 2018.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn | 292.00 Mn |
| 2 | Regeneron Pharmaceuticals | 85.51 Bn | 77.52 Bn | 3.93 Bn | 230.90 Mn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | -59.00 Mn |
| 4 | Moderna | 58.20 Bn | 53.06 Bn | 52.00 Mn | 15.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | - |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn | 75.45 Mn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | 13.31 Mn |
| 8 | Royalty Pharma | 28.40 Bn | 27.56 Bn | - | - |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | 1.90 Mn |
| 10 | Savara | 1.36 Bn | 1.36 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2018 | 2.50 Mn |
| Sep 30, 2018 | -110,000.00 |
| Jun 30, 2018 | -277,000.00 |
| Mar 31, 2018 | -4.56 Mn |
| Dec 31, 2017 | -10.54 Mn |
| Sep 30, 2017 | -117,000.00 |
| Jun 30, 2017 | -470,000.00 |
| Mar 31, 2017 | -237,000.00 |